The IPSS-del(5q): a newly developed prognostic score for MDS with isolated 5q deletion

(1:2)

5Q with Cecilia Parrish / Strategic Planner at The Martin Agency

(4:57)

5q Minus Syndrome: What we know (and what we don't know yet)

(22:59)

5Q with David Baldwin / Lead Guitar at Baldwin\u0026

(10:42)

The influence of TP53 mutations in MDS with isolated 5q deletion

(52)

5Q with Wendy Clark / DDB North America

(7:55)

5Q with Jess Greenwood / R/GA

(5:57)

5Q with Matt Donlon / Founder of UZURV

(3:15)

5Q with David Muhlenfeld / Vice President and Creative Director at The Martin Agency

(4:6)

5Q with Karl Lieberman / Executive Creative Director at Wieden + Kennedy

(6:49)

SINTRA-REV update: early lenalidomide treatment in non-transfusion dependent del(5q) LR-MDS

(1:15)

5Q with Jarrod Higgins, Creative Director at Wieden + Kennedy

(5:2)

5Q with Karen Land Short / Droga5 New York

(4:37)

When to use lenalidomide in MDS patients with and without deletion 5q

(4:21)

5Q with Saneel Radia / Executive Vice President \u0026 Global Head of Consulting at R/GA

(5:21)

5Q with Winston Binch / Deutsch

(10:19)

5Q with Bob Winter and Joe Nio / VSA Partners

(8:53)

Transplantation and Deletion 5q Syndrome: A Case Example

(3:7)

Management of treatment-naïve LR-MDS with isolated 5q deletion (del5q)

(14:50)

Considering Lenalidomide in Non-Del 5q MDS

(7:56)